Safety and efficacy of six months' open label extension post-RCT using the novel cathepsin K inhibitor MIV-711 in patients with knee osteoarthritis

Subjects

Subjects :

medicine.medical_specialty
business.industry
Biomedical Engineering
Osteoarthritis
medicine.disease
law.invention
Rheumatology
Randomized controlled trial
law
Internal medicine
Cathepsin K
Medicine
Orthopedics and Sports Medicine
In patient
Open label
business

Details

ISSN :

10634584

Volume :

27

Database :

OpenAIRE

Journal :

Osteoarthritis and Cartilage

Accession number :

edsair.doi...........fb56837cbf6a1919ef77f202541a03c9

Full Text :

https://doi.org/10.1016/j.joca.2019.02.564